BusinessRaptor Pharmaceutical Presents Results from Meta-Analysis Demonstrating Efficacy of QUINSAIR™ Comparable to Other Approved, Inhaled Antibiotics in Cystic Fibrosis PatientsBy Nasdaq OMXSep 7, 2016, 7:30 AM UTC
BusinessRaptor Pharmaceutical to Present Data on QUINSAIR™ and Other Inhaled Antibiotics at the ERS International CongressBy Nasdaq OMXAug 24, 2016, 11:30 AM UTC
BusinessRaptor’s PROCYSBI® New Drug Submission Accepted by Health Canada with Priority ReviewBy Nasdaq OMXMar 21, 2016, 8:05 PM UTC
BusinessRaptor Announces Qualified Infectious Disease Product (QIDP) Designation for MP-376, Inhaled LevofloxacinBy Nasdaq OMXMar 16, 2016, 11:30 AM UTC
BusinessRaptor Pharmaceutical to Participate in the Cowen and Company 36th Annual Health Care ConferenceBy Nasdaq OMXMar 1, 2016, 12:30 PM UTC
BusinessRaptor Pharmaceutical to Participate in International Rare Disease Week Through Multiple Patient Advocacy ActivitiesBy Nasdaq OMXFeb 29, 2016, 12:30 PM UTC
BusinessRaptor Pharmaceutical Corp. Reports Fourth Quarter and Full Year 2015 Financial Results and Provides 2016 Corporate UpdateBy Nasdaq OMXFeb 25, 2016, 9:05 PM UTC
